Summary This blood cancer discovery highlights a new approach for investigating blood cancers and bone marrow disorders. MPNs or myeloproliferative neoplasms are blood cancers in which the bone marrow makes too many red blood cells, platelets or white blood cells. Currently, there are limited models available to understand the development and response to treatments of […]
How important is fibrosis in myelofibrosis?
by David Wallace What is fibrosis in myelofibrosis? Myelofibrosis is characterized by an accumulation of fibrous tissue (fibrosis) or scar tissue in the bone marrow. As fibrosis increases, it impairs the bone marrow’s ability to produce healthy blood cells. This can cause numerous symptoms, including anemia, fatigue, weakness and an increased risk of bleeding and […]
Dr. Ruben Mesa named to Lead Atrium Health Cancer Program
Atrium Health recently announced Dr. Ruben A. Mesa has been named president and executive director of its cancer service line – which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center – and vice dean for cancer programs at Wake Forest University School of Medicine. Mesa will assume the roles filled by Dr. […]
Theories on Treatment of Polycythemia Vera with Interferon-β
Simple Summary The myeloproliferative neoplasms (MPNs) are chronic blood cancers characterized by elevated blood cell counts and, after decades, the development of bone marrow failure. Blood clots are common and contribute massively to the symptom burden. Treatment with interferon (IFN) alpha-2 normalizes elevated blood cell counts within weeks to months. This treatment has been used […]
Real-World Treatments and Thrombotic Events in U.S. based Polycythemia Vera Patients
Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive medications, are targeted to maintain hematocrit levels < 45% to prevent adverse outcomes. This retrospective observational study examined medical and pharmacy claims of 28,306 PV patients initiating treatment for PV in a data period […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 34
- Next Page »